The relevance of the individual screening for genetic variants in predicting ovarian response

被引:4
|
作者
Lledo, Belen [1 ]
Llacer, Joaquin [2 ]
Blanco, Laura [1 ]
Ortiz, Jose A. [1 ]
Morales, Ruth [1 ]
Fabregat, Ana [1 ]
Guerrero, Jaime [2 ]
Bernabeu, Rafael [1 ,2 ]
机构
[1] Inst Bernabeu Biotech, Mol Biol, Alicante, Spain
[2] Inst Bernabeu Fertil & Gynecol, Reprod Med, Alicante, Spain
来源
PHARMACOGENETICS AND GENOMICS | 2019年 / 29卷 / 09期
关键词
antimullerian hormone receptor 2; oestrogen receptor gene; gene polymorphism; oocyte donor; ovarian stimulation; SINGLE NUCLEOTIDE POLYMORPHISM; ANTI-MULLERIAN HORMONE; ANDROGEN RECEPTOR GENE; REPRODUCTION OUTCOMES; STIMULATION DEPENDS; WOMEN; ESR1; SHBG; ASSOCIATION; PHARMACOGENETICS;
D O I
10.1097/FPC.0000000000000386
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective To investigate if polymorphisms of some genes involved in folliculogenesis predict ovarian response. Methods This prospective randomized study includes 124 egg donors genotyped for six SNPs ESR1 (rs2234693), AMHR2 (rs2002555), GDF-9 (rs10491279 and rs254286), AMH (rs10407022) and LHCBR (rs229327) genes and four STRs in ESR1 rs3138774), SHBG (rs6761), CYP19A1 (rs60271534) and AR genes (CAG repeats in exon 1). All donors followed standard ovarian stimulation protocol using a daily dose of 225 UI. The genotypes obtained were compared with the ovarian stimulation outcome. Results Regarding the number of retrieved oocytes, we found statistical differences for the ESR1 SNP and STR (19.3 +/- 8.9 for TT vs 15.3 +/- 6.2 for CC/CT, P = 0.027; 19.1 +/- 8.3 for 17repeats, P = 0.020). Moreover, women carrying TT in the ESR1 at position c.-397T>C with ESR1 (TA)n=17 retrieved the highest number of oocytes (20.4 +/- 9.3) (P = 0.001). Concerning AMHR2, we observed an association with the length of stimulation (9.1 +/- 1.4 d for AA vs 9.7 +/- 1.3 d for AG/GG, P = 0.021) and gonadotropin received (2050 +/- 319 for AA vs 2188 +/- 299 for AG/GG, P = 0.017). No significant differences were observed for the other polymorphisms (P > 0.05). Conclusion The polymorphisms in ESR1 and AMHR2 genes showed a clear association with the number of retrieved oocytes and the stimulation data, respectively. Our results suggest that polymorphisms in the genes for key reproductive hormones receptors could be used to predict the ovarian response and to personalize the stimulation prior the treatment.
引用
收藏
页码:216 / 223
页数:8
相关论文
共 50 条
  • [41] Blood type, ABO genetic variants, and ovarian cancer survival
    Cozzi, Gabriella D.
    Levinson, Rebecca T.
    Toole, Hilary
    Snyder, Malcolm-Robert
    Deng, Angie
    Crispens, Marta A.
    Khabele, Dineo
    Beeghly-Fadiel, Alicia
    PLOS ONE, 2017, 12 (04):
  • [42] The effects of common genetic variants in oncogenes on ovarian cancer survival
    Quaye, Lydia
    Gayther, Simon A.
    Ramus, Susan J.
    Di Cioccio, Richard A.
    McGuire, Valerie
    Hogdall, Estrid
    Hogdall, Claus
    Blaakr, Jan
    Easton, Douglas F.
    Ponder, Bruce A. J.
    Jacobs, Ian
    Kjaer, Susanne Kruger
    Whittemore, Alice S.
    Pearce, Celeste Leigh
    Pharoah, Paul D. P.
    Song, Honglin
    CLINICAL CANCER RESEARCH, 2008, 14 (18) : 5833 - 5839
  • [43] Penetrance of pathogenic genetic variants associated with premature ovarian insufficiency
    Shekari, Saleh
    Stankovic, Stasa
    Gardner, Eugene J.
    Hawkes, Gareth
    Kentistou, Katherine A.
    Beaumont, Robin N.
    Morseburg, Alexander
    Wood, Andrew R.
    Prague, Julia K.
    Mishra, Gita D.
    Day, Felix R.
    Baptista, Julia
    Wright, Caroline F.
    Weedon, Michael N.
    Hoffmann, Eva R.
    Ruth, Katherine S.
    Ong, Ken K.
    Perry, John R. B.
    Murray, Anna
    NATURE MEDICINE, 2023, 29 (07) : 1692 - +
  • [44] Rare genetic variants potentially involved in ovarian hyperstimulation syndrome
    Katrien Stouffs
    Sari Daelemans
    Samuel Santos-Ribeiro
    Sara Seneca
    Alexander Gheldof
    Ali Sami Gürbüz
    Michel De Vos
    Herman Tournaye
    Christophe Blockeel
    Journal of Assisted Reproduction and Genetics, 2019, 36 : 491 - 497
  • [45] Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer
    Pavanello, Marina
    Chan, Isaac H. Y.
    Ariff, Amir
    Pharoah, Paul D. P.
    Gayther, Simon A.
    Ramus, Susan J.
    CANCERS, 2020, 12 (10) : 1 - 23
  • [46] Genetic variants in Notch signaling pathway and ovarian cancer.
    Xu, Enping
    Lu, Karen H.
    Hildebrandt, Michelle A. T.
    Huang, Maosheng
    Wu, Xifeng
    Liang, Dong
    CANCER RESEARCH, 2013, 73 (08)
  • [47] Rare genetic variants potentially involved in ovarian hyperstimulation syndrome
    Stouffs, Katrien
    Daelemans, Sari
    Santos-Ribeiro, Samuel
    Seneca, Sara
    Gheldof, Alexander
    Gurbuz, Ali Sami
    De Vos, Michel
    Tournaye, Herman
    Blockeel, Christophe
    JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2019, 36 (03) : 491 - 497
  • [48] Penetrance of pathogenic genetic variants associated with premature ovarian insufficiency
    Saleh Shekari
    Stasa Stankovic
    Eugene J. Gardner
    Gareth Hawkes
    Katherine A. Kentistou
    Robin N. Beaumont
    Alexander Mörseburg
    Andrew R. Wood
    Julia K. Prague
    Gita D. Mishra
    Felix R. Day
    Julia Baptista
    Caroline F. Wright
    Michael N. Weedon
    Eva R. Hoffmann
    Katherine S. Ruth
    Ken K. Ong
    John R. B. Perry
    Anna Murray
    Nature Medicine, 2023, 29 : 1692 - 1699
  • [49] In vitro pharmacogenomic study of ovarian cancer finds novel genetic variants associated with response to platinum and taxane therapies
    Fridley, Brooke L.
    Ghosh, Taraswi M.
    Wang, Alice
    Goode, Ellen L.
    Lamba, Jatinder
    CANCER RESEARCH, 2014, 74 (19)
  • [50] Genetic Variants in MicroRNA Biosynthesis Pathways and Binding Sites Modify Ovarian Cancer Risk, Survival, and Treatment Response
    Liang, Dong
    Meyer, Larissa
    Chang, David W.
    Lin, Jie
    Pu, Xia
    Ye, Yuanqing
    Gu, Jian
    Wu, Xifeng
    Lu, Karen
    CANCER RESEARCH, 2010, 70 (23) : 9765 - 9776